Atara Biotherapeutics
ATRA
148 hedge funds and large institutions have $1.7B invested in Atara Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 58 increasing their positions, 44 reducing their positions, and 20 closing their positions.
59% more capital invested
Capital invested by funds: $1.07B → $1.7B (+$632M)
40% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 20
32% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 44
6% more funds holding
Funds holding: 140 → 148 (+8)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.25% less ownership
Funds ownership: 4.44% → 4.18% (-0.25%)
3% less call options, than puts
Call options by funds: $1.76M | Put options by funds: $1.82M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$42.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.8M |
| 3 |
Citigroup
New York
|
+$20.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.5M |
| 5 |
JP Morgan Chase
New York
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$21.3M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$18.5M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$18.1M |
| 4 |
BG
Baupost Group
Boston,
Massachusetts
|
-$15M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$14.8M |
ATRA Hedge Fund Activity: Q4 2020 in Review
148 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2020, worth a combined $1.7B — up 59% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ATRA positions and 20 closed out — a net gain of 8 holders — while 58 added to existing stakes and 44 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $42.7M. The largest seller was Consonance Capital Management, cutting an estimated $21.3M.
- 148 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2020, up from 140 in Q3 2020.
- Funds reported $1.7B of Atara Biotherapeutics stock for Q4 2020, up 59% quarter-over-quarter.
- 28 funds opened new Atara Biotherapeutics positions in Q4 2020 and 20 closed out, a net change of +8 holders.
- The largest Atara Biotherapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $42.7M added.
- The largest Atara Biotherapeutics seller in Q4 2020 was Consonance Capital Management, an estimated $21.3M sold.
Based on aggregated 13F filings for Q4 2020.